Search research articles
Contact Us
Filters
Showing results (31-40 of 72) with videos related to
Page
of 8
Sort By:
Clinical Chemistry
|
December 10, 2016
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome
Daniel Lindholm, Stefan K James, Maria Bertilsson, et al.
Nature Communications
|
May 13, 2026
A deep learning ECG model for identification and localization of occlusion myocardial infarction
Stefan Gustafsson, Antônio H Ribeiro, Daniel Gedon, et al.
JACC. Heart Failure
|
February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
Kieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.
Circulation
|
October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial
Lars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
JACC. Heart Failure
|
July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
Scott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
European Journal of Heart Failure
|
May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D Solomon, Rudolf A de Boer, David DeMets, et al.
Journal of the American College of Cardiology
|
August 30, 2022
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
Muthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
JAMA Cardiology
|
October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
Muthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
Journal of the American College of Cardiology
|
August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
Daniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
JACC. Heart Failure
|
September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Peder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Page
of 8
Search research articles
Search
Showing results (31-40 of 72) with videos related to
Sort By:
Page
of 8
Clinical Chemistry
|
December 10, 2016
Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome
Daniel Lindholm, Stefan K James, Maria Bertilsson, et al.
Nature Communications
|
May 13, 2026
A deep learning ECG model for identification and localization of occlusion myocardial infarction
Stefan Gustafsson, Antônio H Ribeiro, Daniel Gedon, et al.
JACC. Heart Failure
|
February 4, 2022
Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF
Kieran F Docherty, Joanne Simpson, Pardeep S Jhund, et al.
Circulation
|
October 31, 2013
Biomarkers in relation to the effects of ticagrelor in comparison with clopidogrel in non-ST-elevation acute coronary syndrome patients managed with or without in-hospital revascularization: a substudy from the Prospective Randomized Platelet Inhibition and Patient Outcomes (PLATO) trial
Lars Wallentin, Daniel Lindholm, Agneta Siegbahn, et al.
JACC. Heart Failure
|
July 13, 2020
Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial
Scott D Solomon, Pardeep S Jhund, Brian L Claggett, et al.
European Journal of Heart Failure
|
May 29, 2021
Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial
Scott D Solomon, Rudolf A de Boer, David DeMets, et al.
Journal of the American College of Cardiology
|
August 30, 2022
Estimated Long-Term Benefit of Dapagliflozin in Patients With Heart Failure
Muthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
JAMA Cardiology
|
October 3, 2022
Time to Clinical Benefit of Dapagliflozin in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction: A Prespecified Secondary Analysis of the DELIVER Randomized Clinical Trial
Muthiah Vaduganathan, Brian L Claggett, Pardeep Jhund, et al.
Journal of the American College of Cardiology
|
August 12, 2017
Biomarker-Based Risk Model to Predict Cardiovascular Mortality in Patients With Stable Coronary Disease
Daniel Lindholm, Johan Lindbäck, Paul W Armstrong, et al.
JACC. Heart Failure
|
September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Peder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.
Page
of 8